Gufic Biosciences Limited has submitted to the Exchange, Audited (Standalone and Consolidated) Financial Results of the Company for the Quarter and Financial Year ended March 31, 2026
GUFICBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Gufic Biosciences reported FY2026 standalone revenue of Rs 940.48 crore, up 14.7% from Rs 819.81 crore in FY2025. However, profit after tax declined 9.7% to Rs 63.15 crore from Rs 69.93 crore. The company faced rising costs — materials consumed increased to Rs 425.33 crore (up from Rs 344.20 crore) and finance costs surged 58% to Rs 36.61 crore. Q4 FY2026 showed strong sequential improvement with net profit of Rs 20.57 crore vs Rs 7.97 crore in Q4 FY2025. EBITDA margin compressed as total expenses grew faster than revenue. Operating cash flow dropped sharply to Rs 44.02 crore from Rs 122.78 crore in the prior year, driven by a Rs 107.60 crore inventory build-up and Rs 23.63 crore increase in receivables. The Board recommended a dividend of Re 0.10 per share (10%). Auditors issued an unmodified opinion with no qualifications.
Revenue growth is healthy but profit decline and negative operating cash flow generation signal cost pressures and working capital stress. The sharp inventory build-up and increased borrowings (total debt up from Rs 31,037 crore to Rs 38,516 crore) indicate near-term balance sheet strain, which could weigh on the stock despite top-line strength.